Skip to Content
Merck
CN
  • CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis.

CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis.

Rheumatology international (2015-02-24)
Daniel Kotrych, Violetta Dziedziejko, Krzysztof Safranow, Marek Drozdzik, Andrzej Pawlik
ABSTRACT

Chemokines (CXCL) and their receptors play important roles in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to examine the associations between polymorphisms in the CXCL9 (rs3733236 G>A) and CXCL10 (rs8878 A>G) genes and RA. We examined 422 RA patients and 338 subjects as a control group. Single nucleotide polymorphisms (SNPs) in the CXCL9 (rs3733236 G>A) and CXCL10 (rs8878 A>G) genes were genotyped using TaqMan genotyping assays from Life Technologies Genomic. There were no significant differences in distribution of CXCL9 genotypes and alleles between RA patients and control group. Among RA patients, the increased frequency of CXCL10 (rs8878) G allele carriers was detected AG+GG vs AA (p = 0.034; OR 1.49, 95 % CI 1.03-2.13). There were no significant associations of CXCL9 genotypes with age of disease diagnosis rheumatoid factor, erosive disease, and extra-articular manifestations. In case of CXCL10 genotypes, there was the increased frequency of extra-articular manifestations in GG genotype carriers GG vs AA+AG (p = 0.027; OR 1.82, 95 % CI 1.09-3.03). In the multivariate regression analysis, the CXCL10 GG genotype was the independent factor associated with increased probability of extra-articular manifestations development (p = 0.034; OR 1.75, 95 % CI 1.04-3.03). The results of this study suggest the association between CXCL10 gene polymorphism and rheumatoid arthritis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interferon-γ-Inducible Protein-10 human, ≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder